Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics has shown significant revenue growth, with management projecting over 100% revenue growth for the Integrity product line in 2025 compared to 2024, indicating robust demand and market acceptance. Additionally, the company's osteoarthritis pain management revenue outside the U.S. grew by 13% in the first quarter, demonstrating the strength of its international operations. Furthermore, the regenerative solutions segment reported an impressive 41% growth driven by the Integrity patch, highlighting the potential of its innovative product offerings in the orthopedic market.

Bears say

Anika Therapeutics reported revenue of $28.2 million, reflecting an 8.2% decline compared to the same period last year, indicating a troubling trend in performance. Additionally, the company's international osteoarthritis (OA) pain revenue decreased by 10%, exacerbated by order timing and production yield issues, suggesting operational challenges. The ongoing negative news flow over the past 12-18 months further reinforces the company's precarious financial position, contributing to a generally negative outlook for its stock.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.